Clinical Trial

Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19

Completed
View on ClinicalTrials.gov →
Summary
Esophageal cancer radiotherapy requires accurate delineation of the gross tumor volume (GTV) to ensure adequate tumor coverage and to minimize radiation dose to surrounding organs at risk. Computed tomography (CT) is routinely used for target delineation, while positron emission tomography-computed tomography (PET/CT) may provide additional functional information. However, uncertainty in tumor boundaries and inter-observer variation remain clinically relevant issues. Magnetic resonance imaging (MRI) provides improved soft tissue contrast and diffusion-weighted imaging (DWI) information, which may improve visualization of esophageal tumors. This study evaluates whether MRI-based imaging, alone or fused with CT or PET/CT, reduces inter-observer variation in GTV delineation compared with standard CT and PET/CT-based delineation. A total of 21 patients with locally advanced esophageal cancer undergoing standard radiotherapy preparation will undergo MRI simulation in addition to routine CT and PET/CT simulation. Five experienced radiation oncologists will independently delineate the primary tumor GTV on CT, MRI, PET/CT, CT-MRI fusion, and PET/CT-MRI fusion datasets. Inter-observer variation will be assessed using conformity indices and spatial analysis tools.
Trial Details
NCT Number NCT07416825
Lead Sponsor Institute of Oncology Ljubljana
Conditions Esophageal Cancer, Esophageal Carcinoma
Enrollment 23 participants
Start Date 2020-01-01
Primary Completion 2021-06-30 (estimated)
Study Completion 2021-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-18